Cell-based β-lactamase reporter gene assays designed to measure the functional responses of G-protein-coupled receptors (GPCRs) were miniaturized to less than 2 µL total assay volume in a 3456-well microplate. Studies were done to evaluate both receptor agonists and antagonists. The pharmacology of agonists and antagonists for target GPCRs originally developed in a 96-well format was recapitulated in a 3456-well microplate format without compromising data quality or EC 50 /IC 50 precision. These assays were employed in high-throughput screening campaigns, allowing the testing of more than 150,000 compounds in 8 h. The instrumentation used and practical aspects of the assay development are discussed. (Journal of Biomolecular
INTRODUCTION
I N THE PAST SEVERAL YEARS, major pharmaceutical and biotech companies have invested significant time and capital resources on miniaturization technologies for high-throughput screening (HTS)1 to contain costs and increase primary screening throughput. This is driven by several factors. First, there has been a significant increase in the size of corporate chemical compound libraries principally due to mergers and acquisitions, an increasing number of commercially available samples, and the contributions of automated combinatorial chemistry. Second, the number of validated targets has more than tripled during the past decade as a result of the "de-orphanization" of various novel receptors due to advances in genomics and proteomics.2 Third, the availability of precious reagents, such as purified enzymes and custom-labeled products, is often limited in supply or cost prohibitory in large quantities. Finally, the availability of technology itself is a driver as recent developments in instrumentation and assay technologies are only now just beginning to permit the running of whole live cell-based screens in assay volumes of a few microliters. These low volumes, coupled with higher density microplate formats and combined with technological breakthroughs in liquid handling and detection, have enabled the creation of higher throughput systems that require less time to complete screening of large compound libraries against 1 assay. Reduced screening time frequently results in higher data quality, particularly for cell-based assays due to fewer cell passage numbers and improved consistency in day-to-day cell handling.
The ability to miniaturize biological assays has affected HTS in a rather dramatic manner in the past few years. Only 5 years ago, screening was mostly performed in a 96-well microplate format. However, the requirement for increased process efficiency led to a transition to a 384-well plate format. By the year 2000, a majority of pharma companies had implemented at least 1 HTS campaign in a 1536-well plate format, 3 with fluorescent detection methods in particular. 4 In 2002, 50% of Merck's HTS campaigns were implemented in either 1536-or 3456-well plate formats with assay volumes ranging from 1.5 to 8 mL.
Despite all of the advantages, miniaturization poses some limitations of its own. Highly miniaturized assays are almost always "addition-only" assays. This assay protocol format is often referred to as a homogeneous assay and tends to predominate because instrumentation for cell washing and aspiration from 1536-and 3456-well plates either lacks the required reliability or precision or simply does not exist. Depending on the detection technology, the total analytical signal and assay window (signal to background) may also be lower when compared to 96-or 384-well plate formats. Moreover, reagent mixing in high-density formats is limited to diffusion due to the strong effect of surface tension. In addition, special precautions are needed to overcome evaporative effects at the plate edge. Finally, compound addition procedures for whole live cell-based assays present a special challenge. [5] [6] [7] [8] To maintain DMSO assay concentration below the 0.5% v/v tolerated by most cell-based assays, compound transfer volume must be limited to 7.5 to 40 nL of a 100% v/v stock given a 1.5-to 8-µL total assay volume. Currently, the pintool is one of the most popular devices for such purposes, but it usually delivers a set volume that is a function of pin geometry and surface properties, source well depth, and exposure time to the source material. Typical pintool dispensation volumes range from 20 to 100 nL, and reliable transfer is limited to wet contact. 9, 10 Microsyringe action, combined with low-volume, high-precision tips, allows compound transfers of volumes of 100 nL and above and thus is incapable of addressing the compound addition needs of high-density plates for most cell-based assays. Acoustic beam liquid transfer is a new emerging ultra-low-volume compound transfer technology that appears promising but is still in the early phases of development. 11 Piezo crystal action (similar to that found in ink-jet printers) presents an attractive alternative to pintools for low-volume compound transfer suitable for use with cellular assays. [12] [13] [14] [15] We use this noncontact, low-volume (1-20 nL) dispensation method routinely in our work, which, when coupled with high-speed, high-precision reagent dispensing systems, allowed us to overcome the limitations of assay miniaturization.
In addition to the challenges imposed by the physical constraints of delivering small volumes to wells, another challenging aspect relates to detecting responses in a sensitive and timely manner. For example, fluorescence correlation spectroscopy (FCS) offers an ability to monitor interactions of single molecules in femtoliter volumes. FSC has been developed and implemented for protein-DNA, nucleic acid hybrid formation, receptor-ligand interactions, and various enzymatic reactions in 1-µL volumes and with throughputs around 100,000 samples/day. 16, 17 Here we report the results of experiments leading to the miniaturization, optimization, validation, and HTS of G-protein-coupled receptor (GPCR) live cell-based agonist/antagonist assays in a 3456-well format using assay volumes of less than 2 µL that use noncontact, low-volume liquid dispensation methods as well as a high-sensitivity fluorescence detector.
MATERIALS AND METHODS

3456-well nanoplate
Tissue culture-treated 3456-well plates for cell-based assays are currently available commercially (Greiner BioOne, Lake Mary, FL) for cell-based assays. Figure 1 shows the relationship between 96-, 384-, 1536-, and 3456-well plate formats.
A nanoplate (3456-well plate) has 48 rows with 72 wells in each. The well diameter at the bottom is 1.0 mm, and each well can accommodate working assay volumes up to 2.0 µL. Because the βlactamase reporter gene technology 18 requires substrate addition before the detection step, we do not consider the dye addition to be part of the assay volume (which generally brings the final well volume to between 1.4 and 2.0 µL). Plates are black with an optically transparent bottom, and they have minimal background fluorescence in the range of 380 to 550 nm, which makes it possible to use the plate with other filters/modes of detection beyond solely βlactamase applications (405 nm excitation, 460 and 530 nm emission). Although the plates are designed for bottom-read, other detection formats such as top-view macroimaging are also possible. The nanoplate has evolved during the past 3 years, and significant progress has been made to reduce the number of lint particles, reduce bowing, and verify consistent tissue culture treatment. These plates are currently manufactured using Merck-specific tissue culture techniques and parameters.
Chinese hamster ovary (CHO) cells overexpressing the human oxytocin receptor were dispensed to nanoplates at 700 cells/well seeding density. Cells begin attaching in less than 2 h and reach confluence after an overnight incubation. This particular cell line has a doubling time of about 25 h, and cells survive in a tissue culture incubator (37°C, 95% relative humidity [RH], 5% CO 2 ) for at least 48 h while maintaining their response to agonists.
The assay protocol used for oxytocin receptor (OTR) miniaturization is as follows. Cells are plated (700-800 cells/well) in a nanowell assay plate using the reagent dispensing robot (RDR). Assay plates are then incubated overnight in a tissue culture (TC) incubator, 37°C, 5% CO 2 , > 90% RH. Compounds are added using the nanoplate applicator (NPA) the next morning, and plates are incubated for an additional 4 to 5 h in a TC incubator to allow βlactamase expression. CCF4 substrate is added with the RDR, and 
Instrumentation
Two types of hardware systems make up our miniaturized screening platform-the Screen Development System (SDS) and the Ultra-High-Throughput Screening System (UHTSS), both of which were initially developed by Aurora Biosciences of San Diego, California. 19 The SDS serves to streamline assay miniaturization by employing liquid handlers and plate readers identical to those of the UHTSS in their operational principles. It is also where the pharmacology of the target in miniaturized format is characterized and evaluated. Both the SDS and UHTSS are designed to work with 1536-and 3456-well plates, but these systems differ in the degree of integration and throughput. The SDS components are stand-alone workstations in which throughput is limited by a compound transfer rate of about 30 individual samples per hour. The UHTSS is a fully integrated system with its own compound store and central database for sample heredity tracking, with a throughput of 70,000 samples per hour in the most streamlined working scenario.
The SDS consists of the RDR, NPA, and NPR. The UHTSS consists of a store, a transport, 2 incubators, 2 RDRs, an NPR, a hit-profiling robot (HPR), a high-capacity stacking system (HCSS), and a piezo sample distribution robot (PSDR). RDR, NPA, and NPR are not commercially available, and technical information on these instruments is not available in any public domain.
The RDR is designed to add "bulk" reagents, such as cells, buffers, oil, fluorescent substrates, and so forth, to nanoplates (see conceptual diagram in Fig. 2A ). The RDR employs 3 robotic arms with 2 dispensing heads on each arm. This enables the RDR to dispense up to 6 reagents (1 per head). Each head uses 48 microsolenoid valves to dispense pressurized (8.5 psi) reagents. Each valve (tip) addresses 72 wells along its respective row in a nanoplate, with the ability to discretely address individual wells with respect to volume dispensed. The orifice of an individual tip is 100 µm in diameter, enabling dispensation volumes in the range of 0.3 to 2.5 µL per well (0.3-9 µL for 1536), with a coefficient of variation (CV) typically around 12% for a calibrated instrument. Dispensation volume in the aforementioned range is proportional to the open time of the valve and is triggered by an initial 40-V pulse. Assay wells can be uniquely addressed, permitting any one of the reagents to be dispensed to any well at any appropriate volume. A single RDR is plate density specific, meaning that 1 RDR can either be dedicated to a 1536-or 3456well plate format, with a 2.25-or 1.5-mm tip pitch, respectively. Limitations of the RDR include inherent tip-to-tip variability; dead volume of as much as 10 mL per reagent due to long, high cross-section tubing used in liquid plumbing; a large footprint of 3 × 2 m, and a requirement for an intense maintenance and service schedule. The shortcomings of the RDR were recently addressed by the development of the flying reagent dispenser (FRD), 20 which is designed to work with both 1536-and 3456-well plates. The FRD uses 4 separate fluidics paths and 4 tips, with each one capable of addressing an entire plate. Typically, 1 pass-tip combination is used per reagent dispensed. The microsolenoid valve is similar to that in the RDR, but the orifice of each tip has been increased from 200 to 250 µm, fluidics restrictions within the tip have been removed, and the tubing between reagent reservoirs and the tips is much shorter and narrower, permitting a greatly reduced dead volume of about 0.5 mL. The FRD is a mobile bench-top dispenser with a footprint of about 1.5 × 1.0 m. CVs are typically on the order of 3% to 7% (RDR C at its best produces 10%-12% CVs), and an average dispense time for 1 to 4 reagents is 2.5 min for 3456-and 1536-well plates (2 min per reagent for RDR).
The nanoplate applicator is a piezo electric tip-based system ( Fig. 2B ) designed to dispense compounds solubilized in DMSObased solutions into a nanowell plate. The compound sample is aspirated (1-5 µL) through the tip using syringe action. Sample fluid is at atmospheric pressure during dispensation, and periodic pulses applied to the piezo crystal assembly produce compression waves and cause~1-nL internal volume displacements in a tapered glass capillary. [12] [13] [14] [15] About half of that displaced volume is directed down toward the orifice, where the sample is dispensed as individual drops of approximately 500 pL. The frequency of dispense is 100 Hz (100 drops per sec), and the dispense voltage is 65 to 130 V. The drop size is calibrated using the standard curve of a fluorescent dye (fluorescein or Oregon Green™). The NPA is a single-tip instrument that uses an XYZ robotic stage to move assay plates under a stationary tip. Transfer volumes range from 1 to 127 nL (2-255 drops) per programmable event, which corresponds to a DMSO concentration between 0.05% and 6.35% for typical 3456-well assay volumes. A camera and a strobe light are employed to adjust/ verify drop quality, enabling a CV of dispensation under 10% for low (2-12) drop counts. All 3456 wells in a nanowell plate are individually addressable. Dispense time is approximately 13 min to pipet a 32-point dose-response curve covering 5 logs in duplicate. This dispenser is similar to the UHTSS sample dispenser (PSDR) as both use the same piezo tips and control circuitry; however, the NPA has only 1 tip, whereas the PSDR has 4 heads of 96 tips each.
The NPR uses a Xenon ARC lamp as the broad-wavelength light source and sets of notch filters for wavelength selection, and it detects EPI-fluorescence through the bottom of a nanowell in 2 channels simultaneously. A conceptual diagram of the NPR's excitation and detection configuration is depicted in Figure 2C . The reader sensitivity, as tested for 120 pM of fluorescein in a borate buffer (pH 9.2, of 2 µL/well), is greater than 3σ (standard deviation) for separation between signal and background for the green channel (480 nm excitation, 530 nm emission). The CV of repeatedly reading a nanoplate with 1 nM of fluorescein is 2%. Using a stationary optical head and an XY robot, the NPR reads a nanoplate with a speed of 1.5 min per plate, collecting both emission channels simultaneously, each with its own photo multiplier tube (PMT) detector. For β-lactamase assays, 405 nm is used as the excitation and 460/530 nm as the emission wavelengths. A fiberoptic bundle consisting of 6 individual fibers, 3 per PMT, is used for light collection and transmission. Samples are acquired every 2 µm along the bottom of the well. Five hundred data points are acquired per well per channel. The central (geometrically) 300 blue and green values are averaged to yield 1 blue and 1 green value per well. Limitations to the NPR include a single-plate format (3456), a single read per plate (impossibility of kinetic data collection), and a fixed focal plane. The last issue requires an operator to focus collection optics at the median of the wells in the Z (vertical, normal to the plate's plane) direction. All these drawbacks were improved on with the development of the topology-compensating plate reader (tcPR) by Aurora Biosciences. The tcPR prescans the bottom of a plate and reads the plate in a contour-adaptive fashion, maintaining constant separation between the plate bottom and collection optics, allowing compensation for as much as 250 µm corner-to-center plate bowing. The tcPR is both 1536-and 3456-well format compatible and is capable of prescanning for dust and carrying out multiple (kinetic) reads.
Construction of concentrationresponse curves with the NPA
Several factors must be taken into account when developing NPA-based experimental protocols. * One principle consideration is the final concentration of DMSO of the assay, which should typically not exceed 0.5% for cellular assays. To satisfy this requirement, given a 500-pL drop size and a discrete drop count, only 2 to 18 drops per well for ligands/compounds dissolved in 100% DMSO is permissible. Solutions with more than 25% water content were precluded from being used due to diffusion of aspirated compound into the system fluid (90% DMSO, 10% ethanol) because both the NPA and PSDR use direct system fluid to sample contact without an air gap. This system fluid composition works best to prevent the diffusion of low-water content DMSO samples. However, a nonmiscible fluid, or a liquid "plug," can be used in between the sample and system fluid to minimize the diffusion of mostly aqueous solutions with the system fluid. A drop count of 40, or about 20 nL, requires a 50% aqueous solution (50:50 DMSO/water) to stay at or below the 0.5% DMSO concentration limit for cellular assays.
Because the assay plate is open (de-lidded) for tip access, experiments should be limited to about 15 min to minimize the evaporation and pH changes of the assay media, which occur during prolonged exposure to ambient conditions. Thus, it has been our best practice to restrict the experimental scope to a single compound per plate transferred as a 32-point dose-response curve in duplicate. This approach is used simply to minimize the exposure of the plate to the environment. This approach allowed us to use only 64 wells out of a 3456-well plate, and it is not cost-effective. The goal of miniaturizing a whole live cell-based assay was met using fewer than 50 plates for the project. However, the savings of running a 1-million compound library in a 3456-well format would still by far outweigh the cost of nanoplates used for development, especially only if 2 control agonists are available. There is a new commercially available instrument-the Multichannel Piezo Dispenser™ (MPD), by Aurora Instruments-that uses a 96piezo tip array. MPD can create multiple concentration responses in parallel on the same nanoplate. It would still have an intrinsic tip-to-tip variability. To determine the suitability of an assay to identify "hits," our practice is to "spike" known activators or inhib-itors across a plate in a random fashion and assess the ability of the miniaturized assay to find them. Using the NPA and a 3456well plate, the highest number of spiked wells was 16 per compound for 2 compounds to limit the time the plate would be un-lidded.
The sequence of events to produce a compound or ligand titration covering 5 logs is as follows (see Fig. 3 ). A tip wash is followed by the aspiration of a liquid plug (silicon oil: 5-mer of dimethylsiloxane), after which 1 µL of sample is aspirated from the source well with concentration c1 (lowest of the 4). The sample is first dispensed into a predispense well to establish a stable glass-liquid-air interface, and then increasing numbers of drops, 2 to 40, are immediately added in duplicate into a nanowell assay plate. The remaining sample inside the tip is voided into a void well. These steps are then repeated for each additional sample source well (concentrations c2, c3, and c4).
If c1:c2 = 1:20, an overlapping concentration-response segment will result (the last well of a segment will have the same concentration of a compound but not the same DMSO concentration as the first well of the next segment), and the effective doseresponse curve will contain 29 distinct concentrations. In other words, 3 points of the curve are sacrificed as links (duplicates) of repeating concentrations. In the case of c1:c2 = 1:30 and so on, the concentration-response curve will have 32 points, and the concentration range is 30 × 30 × 30 × 20 = 540,000 (5.5 logs). Figure 3 shows the drop counts and placement of the 32-point concentration response dispensed in duplicate on a nanoplate. The compound wells are away from the edges to minimize edge effects, and the curve direction is parallel to that of RDR dispensing (reagents are dispensed by the same RDR tip) to avoid RDR tip-to-tip variability.
Data analysis
A sigmoidal dose-response curve with a variable hill slope was fitted to the data points using GraphPad Prism 3.0 software.
RESULTS AND DISCUSSION
Assay design
A cell-based assay to identify agonists/antagonists of the human oxytocin receptor (hOTR), a GPCR, was established by developing a stable cell line expressing both the human oxytocin receptor and the reporter gene construct, NFAT/Bla (from Aurora Biosciences). 21 Stimulation of these cells with the neuro-hypophyseal hormone oxytocin results in the activation of Gq-dependent intracellular Ca 2+ release and subsequent NFAT activation, culminating in the transcription and translation of the β-lactamase gene. 18, 22 Beta-lactamase activity is detected using the fluorogenic fluorescence resonance energy transfer (FRET) substrate, CCF4, in which a cephalosporin core links 7-hydroxy-coumarin to a fluorescein. 18 In the intact substrate molecule, excitation of the coumarin results in FRET to the fluorescein, which emits a green light at 530 nm. Cleavage of CCF4 by β-lactamase results in spatial separation of the 2 fluorescent dyes, disrupting FRET such that excitation of the coumarin now gives rise to blue fluorescence at 460 nm. Thus, in the hOTR cellular construct receptor, activation increases the expression of β-lactamase, resulting in an increase in blue fluorescence, and unstimulated cells appear green.
Ratiometric reading using the 2-channel output of the NPR permits normalization of signal-minimizing signal variations due to both well-to-well cell number fluctuations and uneven cell distribution within wells, as shown in Figure 4 . Figure 4A corresponds to a normal confluent monolayer, whereas Figure 4B illustrates an uneven cell distribution across the well. Blue and green curves represent individual channel data points read across the given well, whereas the red curve represents green-to-blue ratios. The blue-only (single channel) readout would yield values of 2.5 and 1.5 for each case, respectively, and that would be reported as a 40% loss of signal without an additional image analysis. The formation of the apparent hole of missing cells in the middle of the well resulted from dye dispensation from RDR, which detached some cells from the bottom of the well. The ratio of green-to-blue signal remains unaffected (3.5), despite imperfect cell distribution in the well. The ratiometric readout can be employed for as few as~100 live NFAT CHO cells (counted under a fluorescent microscope) in a well.
Miniaturization of an agonist assay
A direct comparison of the OTR assay miniaturization in 96-and 3456-well formats using 2 OTR agonists, oxytocin and vasopressin, is shown in Table 1 . Total assay volume was 100 µL and 1.6 µL for 96-and 3456-well plate formats, respectively. The assay protocols were identical with the exception of volumes, which were scaled down by a factor of 62. Incubation times for both formats were the same, and dye (CCF4) was added in 20-µL and 0.32-µL quantities for 96-and 3456-well plate formats, respectively. The reduction of assay volume by 62-fold from the 96-to 3456-well format results in no statistically meaningful reduction in sensitivity or data quality. Compared with gene reporter assays using green fluorescent pro- teins (GFP), 23 2 major factors allow miniaturization of reporter gene β-lactamase assays. First is the amplification mechanism, whereby as few as 100 β-lactamase molecules can change the fluorescence of many more CCF4 substrate molecules, which are loaded at up to a 100-µM cytoplasmic concentration (for CHO cells, CCF4 fluorescence inside the cells is 38 times that of cellular autofluorescence). 18 The other factor is the absorbance and emission properties of fluorescein, 7-hydroxycoumarin, and CCF4 compared to typical GFPs (see Zlokarnik et al. 18 and Cubitt et al. 23 for extinction coefficients, quantum yields, FRET efficiency, and background autofluorescence of GFP). In general, concentration-response curves obtained using the NPA and nanoplates have comparable accuracy as compared to a manual 96-well assay. The significant number of data points produced in a 3456-well format experiment with the NPA may provide more confidence for steep concentration-response curves in which EC 10 to EC 90 falls within a narrow concentration range. Figure 5A illustrates a typical 29-point concentration-response curve for an oxytocin titration in a 3456-well plate (oxytocin was dissolved in 75% DMSO) compared to a manual 11-point 96-well plate assay (Fig. 5B) . The EC 50 value of 0.5 nM is in excellent agreement with 96-well results (0.5 nM). Simple inspection of individual channel fluorescence intensity output reveals that at higher concentrations of agonist (here, above 1 nM), there is substantial (~25%) CCF4 substrate depletion, and the assay readout is substrate limited. Normally, for an enzymatic assay, this might be a concern, but for the β-lactamase reporter-based cellular assays, substrate depletion, coupled with the availability of 2 detection channels, offers a unique opportunity to distinguish between true agonist hits (blue-channel increase, green-channel slight decrease), fluorescent artifacts (i.e., lint; both-channel increase), and cytotoxic compounds (both-channel decrease). All 3 combinations can result in increased blue to green ratios. 22 A set of simple in silico data filters can be employed to reduce the number of false positives in primary screening, based on the individual raw channel readings. For the NPR example, in which individual channel voltages are converted to a 0-to 10-V scale, a normal greenchannel (530 nm) voltage for an agonist screen would be around 5 V. For true actives, the green-channel voltage should stay the same or go down slightly, to between 3.5 and 4.5 V. An in silico data filter for the green channel could flag all the hits with green-channel voltage above 8 V. These flagged compounds are most likely fluorescent at the given screening concentration.
The pharmacology of 2 OTR agonists, oxytocin and vasopressin, was compared by generating concentration-response curves for both peptides in parallel, as shown in Figure 6B . Sample images of hOTR CHO cells are displayed at different agonist (OT) concentrations in Figure 6A . The EC 50 values are in good agreement (0.5 nM for OT and 2.2 nM for VAS) with 96-well results of 0.6 nM and 2.0 nM, respectively (data not shown). Perhaps more important, the rank order of potency of the 2 agonists was preserved in the 3456-well format. An example of an OT antagonist concentration-response curve is given in Figure 6C . The value of the IC 50 of 15 nM is in excellent agreement with the 96-well format result (10-30 nM), demonstrating the utility of this assay format both in agonist and antagonist modes.
The ability to identify randomly scattered wells spiked with a control agonist or antagonist compound indicates high instrumentation reliability, assay robustness, and appropriate plate quality in preparation for an HTS campaign against an entire compound library. Therefore, such spiking experiments are an integral part of validating the miniaturized assay prior to primary screening. Both oxytocin and vasopressin were randomly placed in 16 nanoplate. Both agonists were added at 1 µM, the primary screening concentration, which is significantly higher than their EC 50 values. The spiked population of 32 wells was easily identified with a signal to background of about 10 and a %CV of 10 between the spikes (data not shown). Although a dedicated spiking experiment for the EC 50 to EC 90 concentration range of agonists was not performed, the data can be easily derived from multiple 32-point concentration-response plates. For instance, in a span of 2 weeks, 8 oxytocin 32-point concentration responses in duplicate were completed. That data yielded 16 distinct wells with añ EC 50 concentration of agonist. All of those spikes were detected with a %CV of 17. The ability to detect all the positive controls demonstrated that potential hits would not be missed during a screening campaign. A similar result (data not shown) was obtained for the antagonist used in Figure 5C using agonist (oxytocin) added at its EC 80 concentration.
System validation with a set of confirmed NTR hits
The Aurora instrumentation dedicated to 3456-well plates was further validated with another β-lactamase agonist assay using the neurotensin receptor (NTR). 24, 25 The neurotensin receptor is another member of the large GPCR family. 22 A cell line was established expressing both the human neurotensin receptor and the reporter gene construct, NFAT/bla, similar to the cell line expressing the hOTR. Using this cell line, we tested 123 "hits" that were previously identified and confirmed in a 384-well plate screen. Figure 7 shows the correlation results between 384-and 3456well formats for the NTR assay. From a total of 123 compounds, we confirmed 93 hits as > 30% active by ratiometric readout. Of the 30 missed compounds, 25 exhibited a compound-specific decrease in both blue and green channels (indication of cytotoxicity) and were thus deemed inactive in a 3456-well format, but these may have appeared as false positives in a 384-well format due to ratiometric "deviations." The 5 remaining misses were later analyzed in a manual 384-well assay wherein 2 out of 5 were confirmed as marginally active at 20% to 30%. Possible explanations for the discrepancy are compound degradation or aggregation. Incidentally, 15 of the found hits exhibited a compound-specific increase in both blue and green channels (compound fluorescence) and were detected as active, although these are also likely false positives.
Our screening strategy has been to rapidly identify and confirm hits in the primary screen and to follow up with another independent detection method to greatly reduce the number of detection artifacts and eliminate compounds with off-target activities. Here, the 3 compounds that had previously been confirmed in the secondmessenger assay (Ca + measurement using fluorometric imaging plate reader [FLIPR]) were successfully identified in the 3456-well assay (data not shown). The similarity of the OTR and NTR reporter constructs enables them to serve as mutual counterscreens. A compound, which appears specific for NTR, is illustrated in Figure 8 . The UHTSS informatics screen illustrates a 2-color gradient of agonist activity whereby the darker the color, the higher the activity. In the example shown, compound B appears as NTR specific. Compound A either acts on both cell lines postreceptor, possibly causing receptor-independent Ca 2+ ion release, or acts downstream in the pathway, leading to β-lactamase transcription/translation. Pure DMSO was used as a toxicity control. All of the results were confirmed visually with a fluorescent microscope. The remainder of the plate served as a negative control. It is possible to perform a screen and a counterscreen on the same plate with a common set of robotic operations as long as the assay protocols are amenable.
Other applications of the UHTSS methodology
Typically, cells and another biological reagent are dispensed on top of previously preplated compounds, the plates are incubated in a TC incubator for 12 to 24 h to allow cells to adhere, CCF4 dye is added, and dual-channel fluorescence is detected following 1 h of room-temperature incubation. Utilization of suspension cell assays is beneficial over adherent cell assays when using the UHTSS instrumentation. These advantages include running an entire assay in less than 6 h (per plate), which is particularly beneficial for agonist-mode assays in which prolonged incubation with receptor agonists may induce receptor desensitization, and reducing evaporation and toxicity effects. In addition, it would permit running cell-based assays without a need for a particular tissue culture treatment of assay plates for a given cell line. Cell line development usually consists of a clonal selection of cells with an appropriate pharmacological profile in suspension.
An example of a suspension-mode GPCR antagonist screen in a 3456-well format is given in Figure 9 . Cells were dispensed into nanoplates that had been prepopulated with 5 nL of 2-mM test compounds (solvent is 75% DMSO), resulting in a screening concentration of 1.4 µM in a 1.8-µL assay volume. Cells were subsequently stimulated with an EC 70 concentration of agonist. A Z′ value of 0.8 is similar to that in the 96-and 384-well plate formats. Signal to noise ranged from 5-to 7-fold, without background substraction, maintaining a Z factor (compound field) of~0.75 throughout the screen (Fig. 9C ). All the reagents were dispensed using the FRD, and the tcPR detector was used for signal detection. Three sigma (standard deviation) from the median of the sample field were below 20% inhibition for all plates, allowing a 30% inhibition cutoff to be used for the identification of hits, yielding a hit rate of 0.15%. Thirty percent of primary hits were later confirmed 
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A in triplicate in a 384-well plate format using the same β-lactamase assay. In addition to the assays listed here, several biochemical and nuclear receptor cell-based screens were also implemented in a production mode. 
CONCLUSIONS
Several whole live cell-based GPCR assays were successfully miniaturized into the 3456-well plate format using the SDS. The performance of these miniaturized assays is comparable to the 96well format both in terms of signal-to-background and EC/IC 50 values. Ultra-HTS could be immediately performed on UHTSS. We were able to successfully miniaturize live cell-based functional GPCR assays to volumes of less than 2 µL using the β-lactamase assay technology combined with some of the most advanced fluorescent detection and microdispensation technologies available. This combination of reporter gene biology and advanced hardware routinely allows us to run primary screens with a throughput of up to 200,000 assay wells/day at a cost of 7 cents per well.
